drugset / Trial / NCT00669643

Summary

The purpose of this randomized trial is to verify if leprosy patients, despite of their classification, can be treated with the same regimen without compromising patient cure and acceptability of the treatment. At present, patients classified as multibacillary leprosy are treated for 12 months with three drugs, and patients classified as paucibacillary leprosy are treated for 6 months with two drugs. The study is going to test a unified regimen for paucibacillary and multibacillary patients by treating leprosy patients with three drugs for 6 doses.

Timeline

Start
2007-02
Primary completion
2012-09
Completion
2016-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofazimine Small molecule 25 mg
Subject Clofazimine Small molecule 50 mg
Subject Clofazimine Small molecule 150 mg
Subject Clofazimine Small molecule 300 mg
Comparator Dapsone Small molecule 50 mg
Comparator Dapsone Small molecule 100 mg
Comparator Rifampin Small molecule 450 mg
Comparator Rifampin Small molecule 600 mg

Indications